Nuvation Bio/$NUVB
13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX
About Nuvation Bio
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
Ticker
$NUVB
Sector
Primary listing
NYSE
Industry
Pharmaceuticals
Headquarters
Employees
273
ISIN
US67080N1019
Website
Nuvation Bio Metrics
BasicAdvanced
$762M
-
-$2.03
1.37
-
Price and volume
Market cap
$762M
Beta
1.37
52-week high
$3.97
52-week low
$1.54
Average daily volume
7.8M
Financial strength
Current ratio
9.012
Quick ratio
8.852
Long term debt to equity
0.915
Total debt to equity
2.721
Interest coverage (TTM)
-522.44%
Profitability
EBITDA (TTM)
-205.427
Gross margin (TTM)
16.29%
Net profit margin (TTM)
-5,534.21%
Operating margin (TTM)
-1,883.38%
Revenue per employee (TTM)
$40,000
Management effectiveness
Return on assets (TTM)
-23.33%
Return on equity (TTM)
-119.66%
Valuation
Price to revenue (TTM)
61.059
Price to book
1.81
Price to tangible book (TTM)
1.83
Price to free cash flow (TTM)
-4.246
Free cash flow yield (TTM)
-23.55%
Free cash flow per share (TTM)
-52.75%
Growth
Earnings per share change (TTM)
540.90%
3-year earnings per share growth (CAGR)
68.96%
What the Analysts think about Nuvation Bio
Analyst ratings (Buy, Hold, Sell) for Nuvation Bio stock.
Bulls say / Bears say
The U.S. FDA approved Nuvation Bio's taletrectinib (Ibtrozi) for treating ROS1-positive non-small cell lung cancer, potentially expanding the company's market presence and revenue streams. (reuters.com)
Nuvation Bio secured up to $250 million in non-dilutive financing from Sagard Healthcare Partners, strengthening its financial position for the U.S. commercial launch of taletrectinib and further pipeline development. (businesswire.com)
Analysts project taletrectinib could achieve peak revenues of up to $640 million by 2034, indicating strong market potential and future profitability. (reuters.com)
Following the FDA approval of taletrectinib, Nuvation Bio's stock price declined by 17.4%, suggesting investor concerns over commercialization challenges or market competition. (reuters.com)
The company reported a net loss of $49.4 million for Q4 2024, a significant increase from the $13.8 million loss in the same period the previous year, raising concerns about financial sustainability. (businesswire.com)
Analyst downgrades, such as HC Wainwright lowering their price target from $11.00 to $10.00, may reflect skepticism about the company's near-term growth prospects. (defenseworld.net)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.
Nuvation Bio Financial Performance
Revenues and expenses
Nuvation Bio Earnings Performance
Company profitability
Nuvation Bio News
AllArticlesVideos
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for IBTROZI™ (taletrectinib), Manufactured by Nuvation Bio Inc.
GlobeNewsWire·1 month ago
US FDA approves Nuvation Bio's lung cancer therapy
Reuters·1 month ago
U.S. Food and Drug Administration Approves Nuvation Bio's IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Nuvation Bio stock?
Nuvation Bio (NUVB) has a market cap of $762M as of July 18, 2025.
What is the P/E ratio for Nuvation Bio stock?
The price to earnings (P/E) ratio for Nuvation Bio (NUVB) stock is 0 as of July 18, 2025.
Does Nuvation Bio stock pay dividends?
No, Nuvation Bio (NUVB) stock does not pay dividends to its shareholders as of July 18, 2025.
When is the next Nuvation Bio dividend payment date?
Nuvation Bio (NUVB) stock does not pay dividends to its shareholders.
What is the beta indicator for Nuvation Bio?
Nuvation Bio (NUVB) has a beta rating of 1.37. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.